Bilateral Cystoid Macular Edema with Zanubrutinib Therapy: A Case Report

Abstract We present a patient with recurrent mantle cell lymphoma (MCL) who was treated with zanubrutinib, a Bruton’s tyrosine kinase inhibitor. He subsequently developed bilateral cystoid macular edema (CME) in both eyes. This is the first report of CME in a patient with MCL who was treated with za...

Full description

Saved in:
Bibliographic Details
Published inCase reports in oncology Vol. 16; no. 1; pp. 525 - 530
Main Authors Pennipede, Dante, Sciulli, Harrison, Ajlan, Radwan
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.01.2023
Karger Publishers
Subjects
Case Report
Case reports
Collaboration
cystoid macular edema
Edema
Glaucoma
Lymphoma
mantle cell lymphoma
Nervous system
Oncology
Patients
Retina
Signal transduction
Steroids
Tomography
Transplants & implants
zanubrutinib
Case report
Cystoid macular edema
Zanubrutinib
Mantle cell lymphoma
Online AccessGet full text

Cover

More Information
Summary:Abstract We present a patient with recurrent mantle cell lymphoma (MCL) who was treated with zanubrutinib, a Bruton’s tyrosine kinase inhibitor. He subsequently developed bilateral cystoid macular edema (CME) in both eyes. This is the first report of CME in a patient with MCL who was treated with zanubrutinib. CME was refractory to topical corticosteroid therapy, but sub-Tenon’s steroid injections and holding off zanubrutinib managed to decrease the CME. Treatment managed to prevent further vision loss but did not restore lost vision. The prompt ophthalmic exam is recommended for patients on zanubrutinib with decreased vision.
ISSN:1662-6575
1662-6575
DOI:10.1159/000529069